A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome
Andrew H. Wei(The Royal Melbourne Hospital), Meagan A. Jacoby(MACOM (United States)), Uma Borate(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Pierre Péterlin(Hotel Dieu Hospital), Wan‐Jen Hong, Jason G. Harb(AbbVie (United States)), Poonam Tanwani(AbbVie (United States)), Maria R. Baer(University of Maryland, Baltimore), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Joseph G. Jurcic(Memorial Sloan Kettering Cancer Center), Florian Nolte(Heidelberg University), Olatoyosi Odenike(University of Chicago), Ying Zhou(Tongji University), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Johannes Wolff(The University of Texas MD Anderson Cancer Center), Uwe Platzbecker(National Center for Tumor Diseases), Chun Yew Fong(Olivia Newton-John Cancer Wellness & Research Centre), Martin Dunbar(AbbVie (United States))
Cited by 46
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k